Regeneron Pharmaceuticals Announces 6.8% Dividend Increase
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 02 2026
0mins
Should l Buy REGN?
Source: seekingalpha
- Dividend Increase: Regeneron Pharmaceuticals declares a quarterly dividend of $0.94 per share, marking a 6.8% increase from the previous $0.88, demonstrating the company's ongoing commitment to stable cash flow and shareholder returns.
- Yield Metrics: The forward yield of this dividend stands at 0.51%, reflecting the company's attractiveness in the current market environment, which may draw in more investors seeking stable income.
- Payment Schedule: The dividend is payable on March 5, with a record date of February 20 and an ex-dividend date also set for February 20, ensuring shareholders receive their earnings promptly.
- Future Outlook: Regeneron anticipates double-digit growth in 2026 and plans to initiate 18 new Phase III studies, expecting four FDA approvals, indicating a proactive approach in research and market expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 777.250
Low
637.00
Averages
808.50
High
1057
Current: 777.250
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regeneron Partners with TriNetX to Enhance Genomic Data Access
- Strategic Partnership: Regeneron has entered into a collaboration with TriNetX, gaining exclusive access to integrate its genomic and proteomic datasets with TriNetX's electronic health data network, which encompasses approximately 300 million patients, significantly enhancing drug development capabilities.
- Data Expansion Initiative: This partnership will expand Regeneron's electronic health record-linked genomic and proteomic database, reinforcing its leadership in drug development and laying the groundwork for future digital health solutions.
- Investment and Resource Integration: Regeneron plans to invest up to $200 million in TriNetX, leveraging combined data resources to enhance AI training algorithms, thereby accelerating the discovery and development of innovative drugs.
- Industry Impact Enhancement: This collaboration not only strengthens Regeneron's competitive position in the biotechnology sector but also drives the development of digital health solutions to meet the growing demands of consumers and healthcare providers.
See More
TriNetX Partners with Regeneron for Health Data Access
- Data Collaboration Opportunity: TriNetX and Regeneron have formed a strategic partnership, granting Regeneron access to health records of 300 million anonymized patients, significantly enhancing its drug discovery and development capabilities while driving innovation in digital health solutions.
- Genomic Data Expansion: This collaboration enables Regeneron to integrate its genomic and proteomic data with TriNetX's health record data, thereby expanding its globally leading genomic database and further advancing new drug development.
- Investment and Technology Integration: Regeneron plans to invest up to $200 million in TriNetX, leveraging TriNetX's global healthcare data network to enhance its data analytics capabilities in drug development, thereby accelerating the training and application of AI algorithms.
- Industry Impact Enhancement: By collaborating with TriNetX, Regeneron not only accelerates drug development but also lays the groundwork for future digital health solutions, enhancing its competitiveness in the biotechnology sector.
See More
Regeneron Partners with TriNetX for Data Collaboration
- Data Connectivity Opportunity: Regeneron's collaboration with TriNetX enables the integration of genomic and proteomic data with TriNetX's 300 million de-identified electronic health records, significantly expanding its global genomic database and driving drug discovery and development.
- Investment and Growth: Regeneron plans to invest up to $200 million in this partnership to support innovation in digital health solutions, which is expected to enhance its market competitiveness in the biotechnology sector.
- Privacy Protection Measures: During the data matching process, Regeneron will adhere to privacy regulations such as HIPAA and GDPR, ensuring data security and compliance, thereby enhancing public trust in its data usage.
- Technological Integration Advantage: By combining TriNetX's global healthcare data network with Regeneron's genomic technologies, both parties aim to advance new drug development, improve treatment outcomes, and meet the growing health demands of patients.
See More
Regeneron Partners with TriNetX for Enhanced Drug Discovery
- Strategic Collaboration: Regeneron has entered into a partnership with TriNetX, gaining exclusive access to connect large-scale genomic and proteomic data with TriNetX's global electronic health record network, which is expected to significantly enhance its drug discovery and development capabilities.
- Data Resource Expansion: This collaboration will enable Regeneron to access health data from approximately 300 million de-identified patients, further expanding its world-leading genomic and proteomic EHR-linked database, thereby driving innovation in drug development.
- AI-Powered Health Solutions: By integrating TriNetX's data, Regeneron will leverage AI algorithms to develop future digital health solutions, enhancing health management for patients and providers, which holds significant market potential.
- Investment Commitment: Regeneron will invest up to $200 million in this collaboration, demonstrating its strong commitment to advancing drug development and digital health solutions, which is expected to accelerate its leadership position in the biotechnology sector.
See More
Regeneron Partners with TriNetX for Enhanced Drug Discovery
- Strategic Collaboration: Regeneron has partnered with TriNetX, gaining exclusive access to connect large-scale genomic and proteomic data with TriNetX's global electronic health record network, which is expected to significantly enhance drug discovery and development capabilities.
- Data Resource Expansion: This collaboration will enable Regeneron to access health data from approximately 300 million de-identified patients, further expanding its world-leading EHR-linked genomic and proteomic database, thereby driving innovative drug development.
- AI Empowerment for Future Health: By integrating TriNetX's health data, Regeneron will leverage AI algorithms to optimize digital health solutions, enhancing health management capabilities for consumers, patients, and providers, which has profound market implications.
- Investment in Innovation: Regeneron plans to invest up to $200 million in this collaboration, demonstrating its strong commitment to driving innovation and accelerating drug development, further solidifying its leadership position in the biotechnology sector.
See More
FDA Approves Extended Dosing Schedule for Eylea HD
- Extended Dosing Approval: The US FDA has approved Eylea HD (aflibercept) to be dosed as infrequently as every 20 weeks for wet age-related macular degeneration and diabetic macular edema after one year of successful treatment, significantly reducing the frequency of administration for patients.
- Optimized Treatment Regimen: The new regimen stipulates monthly dosing for the first three months, followed by every two to three months, allowing most patients to require only two to three doses annually after one year of treatment, greatly enhancing patient adherence and quality of life.
- Clinical Trial Validation: The approval of the extended dosing schedule is based on two-year data from the PULSAR and PHOTON trials, which demonstrated sustained efficacy, further solidifying Eylea HD's competitive position in the market.
- Broad Market Potential: With the reduced dosing frequency, Eylea HD is expected to attract more patients, enhancing Regeneron's market share in the ophthalmic drug sector and potentially driving future revenue growth.
See More
Regeneron Partners with TriNetX to Enhance Genomic Data Access
- Strategic Partnership: Regeneron has entered into a collaboration with TriNetX, gaining exclusive access to integrate its genomic and proteomic datasets with TriNetX's electronic health data network, which encompasses approximately 300 million patients, significantly enhancing drug development capabilities.
- Data Expansion Initiative: This partnership will expand Regeneron's electronic health record-linked genomic and proteomic database, reinforcing its leadership in drug development and laying the groundwork for future digital health solutions.
- Investment and Resource Integration: Regeneron plans to invest up to $200 million in TriNetX, leveraging combined data resources to enhance AI training algorithms, thereby accelerating the discovery and development of innovative drugs.
- Industry Impact Enhancement: This collaboration not only strengthens Regeneron's competitive position in the biotechnology sector but also drives the development of digital health solutions to meet the growing demands of consumers and healthcare providers.
See More
TriNetX Partners with Regeneron for Health Data Access
- Data Collaboration Opportunity: TriNetX and Regeneron have formed a strategic partnership, granting Regeneron access to health records of 300 million anonymized patients, significantly enhancing its drug discovery and development capabilities while driving innovation in digital health solutions.
- Genomic Data Expansion: This collaboration enables Regeneron to integrate its genomic and proteomic data with TriNetX's health record data, thereby expanding its globally leading genomic database and further advancing new drug development.
- Investment and Technology Integration: Regeneron plans to invest up to $200 million in TriNetX, leveraging TriNetX's global healthcare data network to enhance its data analytics capabilities in drug development, thereby accelerating the training and application of AI algorithms.
- Industry Impact Enhancement: By collaborating with TriNetX, Regeneron not only accelerates drug development but also lays the groundwork for future digital health solutions, enhancing its competitiveness in the biotechnology sector.
See More
Regeneron Partners with TriNetX for Data Collaboration
- Data Connectivity Opportunity: Regeneron's collaboration with TriNetX enables the integration of genomic and proteomic data with TriNetX's 300 million de-identified electronic health records, significantly expanding its global genomic database and driving drug discovery and development.
- Investment and Growth: Regeneron plans to invest up to $200 million in this partnership to support innovation in digital health solutions, which is expected to enhance its market competitiveness in the biotechnology sector.
- Privacy Protection Measures: During the data matching process, Regeneron will adhere to privacy regulations such as HIPAA and GDPR, ensuring data security and compliance, thereby enhancing public trust in its data usage.
- Technological Integration Advantage: By combining TriNetX's global healthcare data network with Regeneron's genomic technologies, both parties aim to advance new drug development, improve treatment outcomes, and meet the growing health demands of patients.
See More
Regeneron Partners with TriNetX for Enhanced Drug Discovery
- Strategic Collaboration: Regeneron has entered into a partnership with TriNetX, gaining exclusive access to connect large-scale genomic and proteomic data with TriNetX's global electronic health record network, which is expected to significantly enhance its drug discovery and development capabilities.
- Data Resource Expansion: This collaboration will enable Regeneron to access health data from approximately 300 million de-identified patients, further expanding its world-leading genomic and proteomic EHR-linked database, thereby driving innovation in drug development.
- AI-Powered Health Solutions: By integrating TriNetX's data, Regeneron will leverage AI algorithms to develop future digital health solutions, enhancing health management for patients and providers, which holds significant market potential.
- Investment Commitment: Regeneron will invest up to $200 million in this collaboration, demonstrating its strong commitment to advancing drug development and digital health solutions, which is expected to accelerate its leadership position in the biotechnology sector.
See More
Regeneron Partners with TriNetX for Enhanced Drug Discovery
- Strategic Collaboration: Regeneron has partnered with TriNetX, gaining exclusive access to connect large-scale genomic and proteomic data with TriNetX's global electronic health record network, which is expected to significantly enhance drug discovery and development capabilities.
- Data Resource Expansion: This collaboration will enable Regeneron to access health data from approximately 300 million de-identified patients, further expanding its world-leading EHR-linked genomic and proteomic database, thereby driving innovative drug development.
- AI Empowerment for Future Health: By integrating TriNetX's health data, Regeneron will leverage AI algorithms to optimize digital health solutions, enhancing health management capabilities for consumers, patients, and providers, which has profound market implications.
- Investment in Innovation: Regeneron plans to invest up to $200 million in this collaboration, demonstrating its strong commitment to driving innovation and accelerating drug development, further solidifying its leadership position in the biotechnology sector.
See More
FDA Approves Extended Dosing Schedule for Eylea HD
- Extended Dosing Approval: The US FDA has approved Eylea HD (aflibercept) to be dosed as infrequently as every 20 weeks for wet age-related macular degeneration and diabetic macular edema after one year of successful treatment, significantly reducing the frequency of administration for patients.
- Optimized Treatment Regimen: The new regimen stipulates monthly dosing for the first three months, followed by every two to three months, allowing most patients to require only two to three doses annually after one year of treatment, greatly enhancing patient adherence and quality of life.
- Clinical Trial Validation: The approval of the extended dosing schedule is based on two-year data from the PULSAR and PHOTON trials, which demonstrated sustained efficacy, further solidifying Eylea HD's competitive position in the market.
- Broad Market Potential: With the reduced dosing frequency, Eylea HD is expected to attract more patients, enhancing Regeneron's market share in the ophthalmic drug sector and potentially driving future revenue growth.
See More
